Labour Intrapartum Analgesia with IV PCA Using Remifentanil v4
The objective of this guideline is to provide a clear explanation and instruction for the safe setup initiation use and discontinuation of Remifentanil PCA for labour analgesia in the Delivery Suite.
This guideline also details the management strategy in the event of complications and side effects from using Remifentanil
Clinical GuidelinesThis guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes.
The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document.